All In Biotech

Drug Trial Radar · NCT03869632

First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors

First in Human Dose Escalation Study of YL-13027 Monotherapy in Subjects With Advanced Stage Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

36

Planned (sponsor's estimate)

Start

Mar 19, 2019

Primary completion

Apr 30, 2021

Study completion Jun 30, 2022

Sponsor

Sponsor type
Industry
First posted
Mar 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

YL-13027-001 is a phase I open-label, first in human, dose escalation study which investigate the tolerability, safety, pharmacokinetics (PK) and efficacy of YL-13027 in subjects with advanced stage solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • YL-13027Drug

    Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 60mg, with escalation to 360mg, and subsequent dose escalation using a modified Fibonacci algorithm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limited toxicities evaluated with NCI-CTC AE v5.0Time frame: within 28 days after the first dose
  2. Adverse events evaluated by NCI CTCAE v5.0Time frame: from the first dose to within 30 days after the last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.